Daniel M. Geynisman, MD, has been announced as the new Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network.
Dr. Geynisman is Associate Professor in the Department of Hematology/Medical Oncology and Chief of the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center. He has a long history of working with NCCN in a variety of roles. He has served as medical oncology section editor for Urologic Oncology: Seminars and Original Investigations since 2018 and has authored more than 130 peer-reviewed publications.
Daniel M. Geynisman, MD
Crystal S. Denlinger, MD
“We are thrilled to welcome Dr. Geynisman into this crucial position for JNCCN,” said Crystal S. Denlinger, MD, NCCN’s Chief Executive Officer. “Our journal fills many important roles when it comes to oncology knowledge-sharing. In addition to publishing exclusive insights and updates for the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), JNCCN publishes rigorous health services research, original investigations, and reviews addressing all aspects of cancer care delivery. Its impact factor grows every year—currently calculated at 13.4, placing it in the top 10% of cancer-related publications. We look forward to seeing what new heights we can reach under [Dr. Geynisman’s] leadership.”
JNCCN is dedicated to improving the quality of cancer care locally, nationally, and globally. The journal is focused on the highest quality original research in the areas of health services, outcomes, quality improvement, and policy.
“It is an honor to be named Editor-in-Chief for JNCCN,” said Dr. Geynisman. “Fox Chase Cancer Center was a founding Member Institution for NCCN, and the opportunity to lead JNCCN is an enormous privilege. I am excited to expand upon the legacy of practice-setting guidelines and outstanding research… and look forward to working with the editorial board and journal staff to continue to build and grow JNCCN as a premier destination for oncology research.”
Dr. Geynisman has a long history of advancing cancer care with NCCN, including serving as a Member on the NCCN Guidelines Panels for both Testicular Cancer and Wilms Tumor. He has reviewed abstracts for presentation at the NCCN Annual Conference, served on various NCCN grant selection committees, and was himself a past recipient of NCCN research grants through NCCN’s Oncology Research Program. He also serves as an ad hoc reviewer for multiple other journals, including The New England Journal of Medicine, European Urology, the Journal of Clinical Oncology, and Cancer.
Margaret Tempero, MD
Dr. Geynisman is succeeding longtime JNCCN Editor-in-Chief Margaret Tempero, MD, of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, who now leads the Cancer Early Detection Initiative at the institution. Under her tenure, the journal emphasized molecular medicine, health services research, and principles in cancer care. It has undergone several redesigns both digitally and in print, including an ongoing shift towards increased online content with a more streamlined, modern look. Learn more about Dr. Tempero’s legacy and achievements in the March 2024 issue of JNCCN.
Dr. Geynisman’s first issue as Editor-in-Chief will be published in June 2024. Visit JNCCN.org to view the newly published May issue, including an official welcome to Dr. Geynisman from the journal’s editorial board and staff.
